Literature DB >> 16545481

Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers.

Mauricio R Loureiro-Silva1, Yasuko Iwakiri, Juan G Abraldes, Omar Haq, Roberto J Groszmann.   

Abstract

BACKGROUND/AIMS: Cirrhotic livers have a deficient vasodilator response to nitric oxide (NO). The vasodilator effect of NO is normally limited by the degradation of its second messenger cyclic guanosine 3', 5' monophosphate by phosphodiesterases. We investigated (1) the phosphodiesterase-5 (PDE-5) expression in normal and cirrhotic rat livers, (2) the location of the deficient response to NO in cirrhotic livers, and (3) the effect of the PDE-5 inhibitor Sildenafil citrate on this deficient response.
METHODS: Normal and ascitic cirrhotic rats were subjected to liver perfusion with continuous measurement of both perfusion and sinusoidal (wedge hepatic) pressures. After incubation with N-monomethyl-l-arginine and pre-constriction with Methoxamine, concentration-response curves to the spontaneous NO donor S-nitroso-N-acetylpenicillamine were obtained in the absence or presence of Sildenafil (10(-8)M).
RESULTS: PDE-5 expression (Western blot) in cirrhotic livers was higher than in normal livers (P=0.042). Compared to normal livers, cirrhotic livers showed a decreased response to S-nitroso-N-acetylpenicillamine in the pre-sinusoidal area (P=0.003) but not in the sinusoidal/post-sinusoidal area (P=0.433). In the presence of Sildenafil, normal and cirrhotic livers showed similar pre-sinusoidal (P=0.419) and sinusoidal/post-sinusoidal (P=0.875) responses to S-nitroso-N-acetylpenicillamine.
CONCLUSIONS: Increased PDE-5 expression is involved in the decreased vascular response to NO in cirrhotic livers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16545481     DOI: 10.1016/j.jhep.2006.01.032

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  11 in total

Review 1.  Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon.

Authors:  Seong Hee Kang; Moon Young Kim; Soon Koo Baik
Journal:  Hepatol Int       Date:  2017-07-11       Impact factor: 6.047

2.  Sildenafil has no effect on portal pressure but lowers arterial pressure in patients with compensated cirrhosis.

Authors:  Puneeta Tandon; Irteza Inayat; Michael Tal; Marcelo Spector; Martha Shea; Roberto J Groszmann; Guadalupe Garcia-Tsao
Journal:  Clin Gastroenterol Hepatol       Date:  2010-02-06       Impact factor: 11.382

3.  Absence of Nogo-B (reticulon 4B) facilitates hepatic stellate cell apoptosis and diminishes hepatic fibrosis in mice.

Authors:  Keitaro Tashiro; Ayano Satoh; Teruo Utsumi; Chuhan Chung; Yasuko Iwakiri
Journal:  Am J Pathol       Date:  2013-01-09       Impact factor: 4.307

4.  Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressure.

Authors:  Hui-Chun Huang; Omar Haq; Teruo Utsumi; Supatsri Sethasine; Juan G Abraldes; Roberto J Groszmann; Yasuko Iwakiri
Journal:  J Cell Mol Med       Date:  2012-05       Impact factor: 5.310

5.  Proteomic identification of S-nitrosylated Golgi proteins: new insights into endothelial cell regulation by eNOS-derived NO.

Authors:  Panjamaporn Sangwung; Todd M Greco; Yanzhuang Wang; Harry Ischiropoulos; William C Sessa; Yasuko Iwakiri
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

6.  Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver.

Authors:  Leonie Halverscheid; Peter Deibert; René Schmidt; Hubert E Blum; Torsten Dunkern; Benedikt H J Pannen; Wolfgang Kreisel
Journal:  BMC Gastroenterol       Date:  2009-09-18       Impact factor: 3.067

7.  Sildenafil ameliorates biomarkers of genotoxicity in an experimental model of spontaneous atherosclerosis.

Authors:  Bianca P Rodrigues; Bianca P Campagnaro; Camille M Balarini; Thiago M C Pereira; Silvana S Meyrelles; Elisardo C Vasquez
Journal:  Lipids Health Dis       Date:  2013-08-28       Impact factor: 3.876

8.  Sildenafil attenuates hepatocellular injury after liver ischemia reperfusion in rats: a preliminary study.

Authors:  Spyridon Savvanis; Constantinos Nastos; Marios-Konstantinos Tasoulis; Nikolaos Papoutsidakis; Maria Demonakou; Iosifina Karmaniolou; Nikolaos Arkadopoulos; Vassilios Smyrniotis; Kassiani Theodoraki
Journal:  Oxid Med Cell Longev       Date:  2014-06-04       Impact factor: 6.543

9.  Beneficial long term effect of a phosphodiesterase-5-inhibitor in cirrhotic portal hypertension: A case report with 8 years follow-up.

Authors:  Peter Deibert; Adhara Lazaro; Zoran Stankovic; Denise Schaffner; Martin Rössle; Wolfgang Kreisel
Journal:  World J Gastroenterol       Date:  2018-01-21       Impact factor: 5.742

10.  Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.

Authors:  Denise Schaffner; Adhara Lazaro; Peter Deibert; Peter Hasselblatt; Patrick Stoll; Lisa Fauth; Manfred W Baumstark; Irmgard Merfort; Annette Schmitt-Graeff; Wolfgang Kreisel
Journal:  World J Gastroenterol       Date:  2018-10-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.